International Clinical Trial: Irinotecan Liposome (II) as First-Line Maintenance Therapy in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: An Exploratory Clinical Study

Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134566) titled 'Irinotecan Liposome (II) as First-Line Maintenance Therapy in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: An Exploratory Clinical Study' on Oct. 16.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shengjing Hospital of China Medical University

Condition: Gastric/Gastroesophageal Junction Adenocarcinoma

Intervention: Experimental group:Maintenance therapy with irinotecan liposome injection (II) in combination with capecitabine. Irinotecan liposome injection (II) 60 mg/m2 IV on Day 1

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-3...